| 摘要: |
| 目的 筛选芪寄方对流感疫苗免疫增强作用的最佳活性部位。方法 36只BALB/c小鼠随机分为空白组、免疫对照组、芪寄方水提液组、上清液组、醇沉部位组及混合部位组。各组每日灌胃含生药2 g·mL-1的药液0.2 mL,连续7 d后肌肉注射四价流感裂解疫苗(含HA 0.5 μg),2周后加强免疫1次。初免后继续给药至14 d。分别于初免7、14、21 d尾尖采血,28 d采血并取脾,检测血清流感特异性抗体IgG(ELISA法)及脾淋巴细胞增殖率(CCK-8法)。结果 各组小鼠体重均稳定增长,表明芪寄方不同部位对生长状态无明显影响。与免疫对照组相比,水提液、上清液及醇沉组的脾脏指数和胸腺指数有上升趋势,但无统计学差异(P>0.05)。抗体检测显示:水提液组提高初免7 d的IgG水平(P<0.05);上清液组提高7 d和14 d的IgG水平(P<0.05);醇沉组持续提高7、14、21 d的IgG水平(P<0.05),28 d亦有升高趋势;混合组无明显影响。淋巴细胞增殖实验表明,醇沉组和上清液组均能增强LPS及ConA诱导的B/T淋巴细胞增殖。结论 芪寄方醇沉部位可持续提升流感特异性抗体IgG水平,而上清液和醇沉部位均能促进脾T/B淋巴细胞增殖。综合分析,醇沉部位是芪寄方增强流感疫苗免疫效果的最佳活性部位。 |
| 关键词: 芪寄方 有效部位 流感疫苗 免疫增强 淋巴细胞增殖率 |
| DOI:10.13506/j.cnki.jpr.2026.06.004 |
| 基金项目:山东省自然科学基金项目(No.ZR2021QH232);山东中医药大学科学研究基金项目(No.KYZK2024Q27);山东中医药大学2025年硕士研究生提质创新课题(No.YJSTZCX2025054) |
|
收稿日期:2005-06-16
修回日期:2025-07-29
|
|
| Screening of active fraction in Qiji Formula for enhancing immune response to influenza split vaccine |
| WANG Xinhuan1,2,YIN Yiming3,GAO Lina1,LIU Qingzhi1,SHI Xiaolin1,LANG Yanfei1,TIAN Jingzhen1,4 |
| (1.College of Pharmacy,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;2.School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China;3.Shandong Xiehe University,Jinan 250109,China) |
| Abstract: |
| Objective To screen the optimal active fraction of Qiji Formula for enhancing immune response to influenza vaccine. Methods Thirty-six BALB/c mice were randomly divided into six groups: blank control group, immunization control group, Qiji Formula aqueous extract group, supernatant group, alcohol precipitation group, and mixed fraction group. Each group was orally administered the corresponding drug solution (containing 2 g·mL-1 of crude drug, 0.2 mL per mouse) daily for 7 days. Subsequently, the mice were intramuscularly injected with quadrivalent influenza split vaccine (containing 0.5 μg HA), followed by a booster immunization 2 weeks later. After the initial immunization, drug administration continued for a total of 14 days. Blood samples were collected from the tail tip on days 7, 14, and 21 post-initial immunization, while blood and spleen samples were collected on day 28. Serum influenza-specific IgG antibody levels were measured using ELISA, and splenic lymphocyte proliferation rates were assessed via the CCK-8 assay. Results All experimental groups demonstrated consistent body weight gain, indicating that the various fractions of Qiji Formula had no significant effect on the general growth status of the mice. Compared to the immunization control group, the aqueous extract, supernatant, and alcohol precipitation groups showed a tendency toward increased spleen and thymus indices, although these differences were not statistically significant (P>0.05). Antibody analysis revealed that the aqueous extract group significantly enhanced IgG levels at 7 days post-primary immunization (P<0.05), while the supernatant group showed significant IgG elevation at both 7 and 14 days (P<0.05). The alcohol precipitation group exhibited sustained and significant IgG level increases at 7, 14, and 21 days (P<0.05), with an observable upward trend at 28 days, whereas the mixed fraction group demonstrated no significant effects. Lymphocyte proliferation assays further demonstrated that both the alcohol precipitation and supernatant fractions effectively enhanced LPS- and ConA-induced proliferation of B and T lymphocytes. Conclusion The alcohol-precipitated fraction of Qiji Formula demonstrated sustained enhancement of influenza-specific IgG antibody levels, while both the supernatant and alcohol-precipitated fractions promoted the proliferation of splenic T and B lymphocytes. Comprehensive analysis revealed that the alcohol-precipitated fraction represents the optimal active component of Qiji Formula for enhancing the immunopotentiation effect of influenza vaccine. |
| Key words: Qiji Formula Effective fraction Influenza vaccine Immune enhancement Lymphocyte proliferation rate |